Semaglutide, a potent GLP-1 receptor agonist, has shown notable results: the SELECT trial demonstrated that weekly subcutaneous semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACE) even in individuals without diabetes but with established cardiovascular disease and overweight or obesity [4]
, .
Ahrn B, Comas LM, Kumar H, Sargin M, Derving Karsbl J, Jacobsen SH, et al
Prefer to leave your details
Vision-related issues, such as blurred vision, are not mentioned as side effects
On the other hand, Benadryl, known by its generic name diphenhydramine, is an antihistamine used to relieve allergy symptoms